Sodium-glucose cotransporter 2 (SGLT2) inhibitors and non-small cell lung cancer survival.
Juhua LuoMichael HendryxYi DongPublished in: British journal of cancer (2023)
Our large SEER-Medicare linked data study indicates that SGLT2 inhibitors use was associated with improved overall survival of NSCLC patients with pre-existing diabetes. Further studies are needed to confirm our findings and elucidate the possible mechanisms behind the association.